Advertisement Pharmaceutical Business review - Page 307 of 5259 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
February 3, 2026

Aquestive receives FDA CRL for Anaphylm allergic reaction treatment

Aquestive Therapeutics has received a complete response letter (CRL) from the US Food and Drug Administration (FDA) regarding its new drug application (NDA) for Anaphylm, a sublingual film formulation of dibutepinephrine.

The original NDA included 11 clinical studies with approximately 967 total administrations across 411 participants. Credit: Sai Thaw Kyar / Shutterstock.com.